Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Operating Leases (2019 - 2025)

Plus Therapeutics (PSTV) has disclosed Operating Leases for 6 consecutive years, with $31000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Operating Leases fell 63.53% to $31000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $31000.0, a 63.53% decrease, with the full-year FY2024 number at $31000.0, down 63.53% from a year prior.
  • Operating Leases was $31000.0 for Q4 2024 at Plus Therapeutics, down from $40000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $589000.0 in Q2 2020 to a low of $31000.0 in Q4 2024.
  • A 5-year average of $236352.9 and a median of $141000.0 in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: decreased 7.52% in 2021, then tumbled 66.1% in 2024.
  • Plus Therapeutics' Operating Leases stood at $528000.0 in 2020, then decreased by 4.55% to $504000.0 in 2021, then crashed by 72.02% to $141000.0 in 2022, then crashed by 39.72% to $85000.0 in 2023, then plummeted by 63.53% to $31000.0 in 2024.
  • Per Business Quant, the three most recent readings for PSTV's Operating Leases are $31000.0 (Q4 2024), $40000.0 (Q3 2024), and $50000.0 (Q2 2024).